Search company, investor...

Predict your next investment

Corporate Venture
nanfunglifesciences.com

Investments

20

Portfolio Exits

2

Partners & Customers

1

About Nan Fung Life Sciences

Nan Fung Life Sciences life sciences investment platform with a long-term capital commitment from the Nan Fung Group.

Headquarters Location

San Francisco, California, 94107,

United States

Want to inform investors similar to Nan Fung Life Sciences about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Nan Fung Life Sciences News

The Real Estate Problem Holding Back NYC's Life Sciences Industry

May 23, 2022

<img alt="Bisnow/Ellie Meyer Outshine Properties' Bill Hunter, New York Economic Development Corp.'s Susan Rosenthal, Hunter Roberts Construction Group's Brian Aronne, Nan Fung Life Sciences' Matt Powers and SGA's Brooks Slocum." border="0" height="170" src="https://www.biohealthinnovation.org//images/dmvgadmin/the_real_estate_problem_holding_back_nyc_s_life_sciences_industry.png" style="float: right;" title="The_Real_Estate_Problem_Holding_Back_NYC_s_Life_Sciences_Industry.png" width="249" />Life sciences in New York City is poised for growth, but industry leaders said that will only be assured if developers build enough spaces for startups of all sizes. Unless the city can accommodate life sciences companies in their earlier years, when they need less space, experts warn NYC could lose talent to rival life sciences hubs. Image: Bisnow/Ellie MeyerOutshine Properties' Bill Hunter, New York Economic Development Corp.'s Susan Rosenthal, Hunter Roberts Construction Group's Brian Aronne, Nan Fung Life Sciences' Matt Powers and SGA's Brooks Slocum.

Nan Fung Life Sciences Investments

20 Investments

Nan Fung Life Sciences has made 20 investments. Their latest investment was in Ablaze Pharmaceuticals as part of their Series A on November 11, 2021.

CBI Logo

Nan Fung Life Sciences Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/29/2021

Series A

Ablaze Pharmaceuticals

$75M

Yes

12

11/18/2021

Series A - III

Fountain Therapeutics

$15M

No

8

8/3/2021

Series A - II

Engrail Therapeutics

$32M

No

15

5/5/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/10/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/29/2021

11/18/2021

8/3/2021

5/5/2021

3/10/2021

Round

Series A

Series A - III

Series A - II

Series C

Series B

Company

Ablaze Pharmaceuticals

Fountain Therapeutics

Engrail Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$75M

$15M

$32M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

12

8

15

10

10

Nan Fung Life Sciences Portfolio Exits

2 Portfolio Exits

Nan Fung Life Sciences has 2 portfolio exits. Their latest portfolio exit was Oculis on October 17, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/17/2022

Acq - Pending

$99M

1

10/16/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/17/2022

10/16/2020

Exit

Acq - Pending

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

1

10

Nan Fung Life Sciences Partners & Customers

1 Partners and customers

Nan Fung Life Sciences has 1 strategic partners and customers. Nan Fung Life Sciences recently partnered with Celltrion on July 7, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

7/22/2019

Partner

South Korea

Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China – Nan Fung Life Sciences

Leveraging on Nan Fung Group 's strong capital base and long term commitment to the area , Nan Fung Life Sciences aims to become the ideal partner for scientists , entrepreneurs , corporations and investors in the life science space .

1

Date

7/22/2019

Type

Partner

Business Partner

Country

South Korea

News Snippet

Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China – Nan Fung Life Sciences

Leveraging on Nan Fung Group 's strong capital base and long term commitment to the area , Nan Fung Life Sciences aims to become the ideal partner for scientists , entrepreneurs , corporations and investors in the life science space .

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.